Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946853 · ClinicalTrials.gov registry record · NA
Junctional AV Ablation in CRT-D: JAVA-CRT
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02946853: Completed NA study, sponsored by University of Rochester.
NCT02946853 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02946853, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
Cardiac resynchronization therapy (CRT) is a demonstrably effective device intervention for patients with heart failure with reduced ejection fraction and specific indication. However, many patients with heart failure (HF) are unable to maintain sinus rhythm and approximately 30-36% of CRT patients are in atrial fibrillation (AF).
Primary Outcome
Number of patients with reduction ≥ 15% in left ventricular end-systolic volume (LVESV) in each arm of the study.
Interventions
- PROCEDURE Atrioventricular junctional (AVJ) ablation
- DEVICE Cardiac resynchronization therapy - defibrillator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2020-08-31 |
| Phase | NA |
What the finished NCT02946853 record still lists
NCT02946853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Atrioventricular junctional (AVJ) ablation is the first listed.
NCT02946853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02946853 about?
NCT02946853 is a clinical study titled "Junctional AV Ablation in CRT-D: JAVA-CRT". Cardiac resynchronization therapy (CRT) is a demonstrably effective device intervention for patients with heart failure with reduced ejection fraction and specific indication. However, many patients with heart failure (HF) are unable to maintain sinus rhythm and approximately 30-36% of CRT patients ...
What is the current status of trial NCT02946853?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2016-10-01. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT02946853?
The interventions under investigation include: Atrioventricular junctional (AVJ) ablation (PROCEDURE), Cardiac resynchronization therapy - defibrillator (DEVICE).
Who is sponsoring clinical trial NCT02946853?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02946853's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI